Updated results of ALTER-C002: Anlotinib combined with CAPEOX in first-line treatment of patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.

doi:10.1200/JCO.2021.39.15_suppl.e15564

HFCAS OpenIR

	Updated results of ALTER-C002: Anlotinib combined with CAPEOX in first-line treatment of patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.
	Ding, Ke-Feng ; Liu, Yue ; Du, Jinlin ; Zhu, Yuping ; Liu, Zhuo ; Wang, Jianping ; Xu, Dong ; Li, Jun ; Liao, Xiujun ; Sun, Lifeng ; He, Jinjie ; Xiao, Qian ; Wang, Jianwei ; Cao, Hongfeng ; Cai, Yibo ; Cai, Cheng ; Jin, Zhekang ; Yuan, Ying
	2021-05-20
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.e15564
收录类别	SCI
语种	英语
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000708120301229
出版者	LIPPINCOTT WILLIAMS & WILKINS
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/126657
专题	中国科学院合肥物质科学研究院
作者单位	1.Zhejiang Univ, Dept Colorectal Surg & Oncol, Key Lab Canc Prevent & Intervent, Minist Educ,Affiliated Hosp 2, Hangzhou, Peoples R China 2.Zhejiang Univ, Jinhua Hosp, Colorectal Surg, Jinhua, Zhejiang, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Colorectal Surg, Canc Hosp, Hangzhou, Peoples R China 4.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Ding, Ke-Feng,Liu, Yue,Du, Jinlin,et al. Updated results of ALTER-C002: Anlotinib combined with CAPEOX in first-line treatment of patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Ding, Ke-Feng.,Liu, Yue.,Du, Jinlin.,Zhu, Yuping.,Liu, Zhuo.,...&Yuan, Ying.(2021).Updated results of ALTER-C002: Anlotinib combined with CAPEOX in first-line treatment of patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Ding, Ke-Feng,et al."Updated results of ALTER-C002: Anlotinib combined with CAPEOX in first-line treatment of patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).